[A24-75] Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27
Last updated 15.08.2024
Project no.:
A24-75
Commission:
Commission awarded on 09.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A24-75_en
| Project no. | Title | Status |
|---|---|---|
| A24-27 | Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-08-15 A G-BA decision was published.